Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
3 Stocks You Can Keep Forever
10:15am, Sunday, 16'th Apr 2023
AbbVie is expected to recover within two years from Humira's patent cliff. Parker-Hannifin is benefiting from increased aerospace spending.
3 Reasons Why I Regret Selling AbbVie
07:45am, Sunday, 16'th Apr 2023
I sold AbbVie for a tidy profit, but simply doing nothing would have been better. Selling means missing out on dividend income as well as share price gains.
AbbVie: An Investor's Trifecta In Transition
07:35am, Saturday, 15'th Apr 2023
AbbVie is a pharmaceutical giant that is building out its portfolio to look nothing like it did a decade ago, and that is great for investors. In 2023, ABBV's #1 selling drug Humira lost its US patent
3 Dividend Stocks to Buy and Hold for the Next Decade
06:14am, Saturday, 15'th Apr 2023
AbbVie faces near-term challenges but has solid long-term prospects plus an especially attractive dividend. Gilead Sciences' strong free cash flow should enable the company to continue raising its div
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
10:40am, Friday, 14'th Apr 2023
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Why AbbVie (ABBV) Could Beat Earnings Estimates Again
01:42pm, Wednesday, 12'th Apr 2023
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why 2023 Could Be a Tough Year for AbbVie Stock
05:15am, Wednesday, 12'th Apr 2023
Humira's sales are forecast to fall by 37% this year. It may be years before Skyrizi and Rinvoq can make up for the Humira sales drop.
Final Trades: Starbucks, Abbvie, Microsoft & APA Corp.
06:35pm, Tuesday, 11'th Apr 2023
The final trades of the day. With CNBC's Melissa Lee and the Fast Money traders.
AbbVie (ABBV), J&J to Withdraw 2 Blood Cancer Nods for Imbruvica
12:09pm, Monday, 10'th Apr 2023
AbbVie (ABBV)/J&J's (JNJ) decision to withdraw the FDA's accelerated approval for Imbruvica in two blood cancer treatments is based on confirmatory studies data that do not support full approval.
Q1 2023 Dividend Report
07:07am, Monday, 10'th Apr 2023
I topped $1,800 in passive dividend income. Over 19 companies bumped their dividends.
5 High-Yield Dividend Stocks in Warren Buffett's Secret Portfolio You Can Buy Right Now
05:52am, Monday, 10'th Apr 2023
Buffett's "secret portfolio" features stocks owned by Berkshire Hathaway subsidiary New England Asset Management. This portfolio includes two pharma stocks, two financial services stocks, and a teleco
Dividend Champion, Contender, And Challenger Highlights: Week Of April 9
03:20am, Sunday, 09'th Apr 2023
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.
Magic Formula Dividend Portfolio For April
11:03am, Friday, 07'th Apr 2023
The following is a dividend portfolio strategy for large caps that score the highest amongst Joel Greenblatt's Magic Formula screener. The list follows large caps that have dividends.
Nicholas Ward's Dividend Growth Portfolio: Special Fixed Income Edition
12:56am, Friday, 07'th Apr 2023
I'm reviewing my February and March results in this piece. My passive income stream grew by 22.63% in February and by 46.87% in March.
My Dividend Growth Portfolio - Q1 2023 Summary
01:26am, Thursday, 06'th Apr 2023
In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. This is part of being transparent with my readers, so they can see what I hold and its
